Skip to main content
. Author manuscript; available in PMC: 2019 Nov 15.
Published in final edited form as: Infect Control Hosp Epidemiol. 2016 Aug 30;37(11):1288–1301. doi: 10.1017/ice.2016.174

TABLE 10.

Effect of a New Carbapenem-Resistant Enterobacteriaceae (CRE) Definition on the Percent Resistance, by Healthcare-Associated Infection Type and Pathogen Reported to the National Healthcare Safety Network (NHSN), 2014

CRE pathogen, CRE definition CLABSI CAUTI SSI
No. of isolates reported % of isolates testedc % Resistance No. of isolates reported % of isolates testedc % Resistance No. of isolates reported % of isolates testedc % Resistance
Klebsiella (pneumoniae/oxytoca) 2,200 4,725 2,319
 Futurea 77.0 10.0 73.9 9.3 72.6 2.9
 Currentb 73.3 10.9 68.8 9.5 66.0 3.3
Escherichia coli 1,595 10,840 6,816
 Futurea 75.0 1.4 71.5 0.6 73.1 0.4
 Currentb 70.9 1.9 66.6 1.1 66.8 0.7
Enterobacter spp. 1,069 1,641 2,056
 Futurea 76.0 5.2 75.8 6.3 74.5 2.0
 Currentb 70.7 6.6 70.7 6.5 67.3 3.4
All CRE 4,864 17,206 11,191
 Futurea 76.1 6.2 72.6 3.6 73.3 1.2
 Currentb 71.9 7.1 67.6 4.0 66.7 1.8

NOTE. CAUTI, catheter-associated urinary tract infection; CLABSI, central line–associated bloodstream infection; SSI, surgical site infection.

a

In future iterations of this report, the Centers for Disease Control and Prevention will use an updated definition for carbapenem-resistant Enterobacteriaceae (CRE). The future CRE definition includes any Klebsiella pneumoniae, Klebsiella oxytoca, Escherichia coli, or Enterobacter spp. that tested resistant [R] to imipenem, meropenem, doripenem, or ertapenem.

b

Current definition of CRE includes any Klebsiella pneumoniae, Klebsiella oxytoca, Escherichia coli, or Enterobacter spp. that tested intermediate [I] or resistant [R] to imipenem, meropenem, or doripenem.

c

If the percent of isolates tested is less than 70%, caution should be used when interpreting the percent resistance.